Printer Friendly
The Free Library
19,569,808 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ADVISORY/Aventis Behring L.L.C. Announces Successful Results of Large, Pivotal Phase I Clinical Trial For Recombumin(R) 20 Percent.


Medical Editors

ADVISORY...for Wednesday

NOTE TO EDITORS: Multimedia Assets Available With This Story

Include Video and Logo

--(BUSINESS WIRE)

Aventis Behring L.L.C. announced the successful results of its large, pivotal Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained
phase I
 for Recombumin(R) 20 percent. The trial was designed to assess the tolerability tol·er·a·ble  
adj.
1. Capable of being tolerated; endurable.

2. Fairly good; passable. See Synonyms at average.



tol
 of Recombumin(R) 20 percent as a stabilizing stabilizing,
v to hold a limb motionless in order to ground its energy; a standard isometric resistance technique, it releases tension and lengthens muscle fibers.
 component in pharmaceutical and biological products, such as vaccines, recombinant recombinant /re·com·bi·nant/ (re-kom´bi-nant)
1. the new entity (e.g., gene, protein, cell, individual) that results from genetic recombination.

2. pertaining or relating to such an entity. See also under DNA.
 therapies and coatings for medical devices. Get video of Aventis Behring's therapeutic protein products from plasma donation through final production and distribution.

You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?1308

This multimedia news story is for free and unrestricted use on your news or information site (and for print or broadcast too). Visit http://www.newstream.com to download To receive a file transmitted over a network. In any communications session, "download" means receive, and "upload" means send. The download/upload often implies a big/little scenario, in which data is being downloaded from the "big" server into the "little" user's computer.  video, audio, text, graphics, and photos.

If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Oct 4, 2000
Words:163
Previous Article:YOUpowered Adds Three to Senior Management Team.
Next Article:S&P Affirms CP Rating on Giro Multi-Funding Corp.



Related Articles
Aventis Behring and Inhale Announce Orphan Drug Designation and Beginning of Phase I Clinical Trials for a Novel Inhaleable Drug.
Aventis Behring Announces Successful Results for First Recombinant Albumin Phase I Clinical Trial.
Newstream.com digest: New Fannie Mae National Housing Survey: First In-Depth Look at Effect of Internet on Mortgage Industry, Wireless Phone...
HUMAN GENOME/AVENTIS BEHRING TO DEVELOP PLASMA PROTEIN.
Aventis Behring and Inhale Announce Promising Results of a Phase IB Clinical Trial for Inhaleable Alpha1 Proteinase Inhibitor for Hereditary...
Delta Biotechnology's New Protein Technology Adopted by Merck for Investigational Measles, Mumps and Rubella Vaccine.
Aventis Behring Submits Application for FDA Approval of New Intravenous Alpha-1 Antitrypsin to Treat Hereditary Emphysema.
ZymoGenetics Initiates Clinical Trials and Strengthens Proprietary Position for Recombinant Human Factor XIII.
Aventis Behring Spearheads Educational Initiative to Improve Treatment of Hemophilia in Developing Countries.
An overview of the drug development process.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles